Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- Chuikyo Members Oppose Reference Pricing System for LLPs
June 1, 2017
- Payer Reps Push Earlier Application of “Z2” Price Cut for LLPs with Low Gx Rates: Chuikyo
June 1, 2017
- MHLW Advisory Panel Gives Nod to Eli Lilly’s JAK Inhibitor Baricitinib
May 31, 2017
- PhRMA Calls for Expedited Discussions on Inclusion of Vaccines in Public Vaccination Programs
May 31, 2017
- MHLW to Take Strict Action on Xarelto Side Effect Case: Minister
May 31, 2017
- MHLW Orders Label Revisions for Pneumovax NP, 3 Other Products
May 31, 2017
- Lyrica OD Tablets, Other New Dosage Forms to Join NHI Price List on May 31
May 30, 2017
- MHLW Orders Bayer Blanket Probe on Side Effect Reporting
May 30, 2017
- Nusinersen, Tenelia-Canaglu Combo Up for MHLW Panel Review on June 9
May 29, 2017
- Off-Year Revision of NHI Prices “Should Be as Restricted as Possible”: LDP Lawmakers
May 29, 2017
- MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
- MEXT to Probe Company Payments to National Univ. Hospitals: Parliamentary Vice Minister
May 25, 2017
- Suga Tacitly Warns against Watering Down “Annual” Price Revision Plan: CEFP
May 24, 2017
- CEFP Private Members Push Smaller Scope for Price Maintenance Premium, Different Rule for “Me-Too” Meds
May 24, 2017
- Health Minister Pitches Revision to Corporate Eligibility Criteria for Price Maintenance Premium: CEFP
May 24, 2017
- Time Has Arrived to Discuss Formularies at Medical Institutions: MHLW Official
May 23, 2017
- MHLW to Set Deadline to Achieve 80% Generic Goal for “September 2020”
May 23, 2017
- MHLW Council Recognizes Unmet Medical Need for Off-Label Use of 3 Drugs
May 19, 2017
- Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May 19, 2017
- Lawmakers Hear from EFPIA, Say They Didn’t Know Japan Drug Market Would Shrink
May 19, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…